Health Care & Life Sciences » Pharmaceuticals | Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
27,011.00
32,287.00
44,022.00
39,285.30
52,335.80
29,486.10
Cost of Goods Sold (COGS) incl. D&A
1,250.00
1,321.00
8,942.80
4,051.60
3,725.30
4,069.90
Gross Income
25,761.00
30,966.00
35,079.20
35,233.60
48,610.50
25,416.20
SG&A Expense
7,603.00
9,850.00
33,141.00
19,945.40
15,847.40
17,997
EBIT
18,158.00
21,116.00
1,938.30
-
32,763.10
7,419.20
Unusual Expense
-
1,335.00
1,012.00
1,556.80
7,463.60
2,451
Non Operating Income/Expense
-
-
-
953.90
85.70
2.60
Interest Expense
-
-
4,892.30
10,303.90
6,879.50
1,175.60
Pretax Income
18,411.00
20,321.00
1,467.40
7,566.60
18,516.10
4,047.90
Income Tax
6,556.00
330.00
3,730.70
1,976.80
4,566.40
2,491.20
Consolidated Net Income
24,967.00
20,651.00
2,263.20
5,589.80
13,949.70
1,556.70
Net Income
24,967.00
20,651.00
2,263.20
5,589.80
13,949.70
1,556.70
Net Income After Extraordinaries
24,967.00
20,651.00
2,263.20
63,049.10
22,184.30
2,409.50
Net Income Available to Common
24,967.00
20,651.00
2,263.20
51,869.40
4,322.40
703.80
EPS (Basic)
1.02
0.82
0.09
1.12
0.22
0.03
Basic Shares Outstanding
24,558.70
25,336.10
25,943.70
26,197.90
26,572.40
26,773.20
EPS (Diluted)
0.97
0.79
0.09
1.98
0.21
0.03
Diluted Shares Outstanding
25,678.40
26,278.50
26,381.70
26,197.90
26,766.10
26,997.20
EBITDA
19,282.00
21,890.00
7,650.70
16,773.50
34,018.30
8,492.40
Non-Operating Interest Income
253.00
540.00
474.60
71.50
10.40
252.70

About Cipher Pharmaceuticals

View Profile
Address
209 Oak Park Boulevard
Oakville Ontario L6H 0M2
Canada
Employees -
Website http://www.cipherpharma.com
Updated 07/08/2019
Cipher Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the robust and diversified portfolio of commercial and late-stage products. It also acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. Its products include Actikerall, Aclaro, Beteflam, Epuris, Vaniqa, Dermadexin, Pruridexin, Ozenoxacin, Lipofen, Conzip, and Durela.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.